Asensus Surgical (NYSE:ASXC) announced today that it installed a Senhance surgical system at University Hospital Tübingen in Germany.
The Department of Gynecology at the University Hospital Tübingen previously initiated its Senhance Surgical program in December of 2021.
According to a news release, the system will be initially utilized by the gynecology department and, independent of the lease and utilization agreement, the department entered into a research agreement with Asensus focused on collecting procedural and outcomes data for certain gynecologic procedures performed with the Senhance system.
“Gynecological procedures require a high level of precision and safety while at the same time utilizing small instruments due to the delicacy and size of the anatomy,” Medical Director of the Department of Gynecology at University Hospital Tübingen Diethelm Wallwiener said in the release. “Senhance is a great addition to our gynecology department as it provides unparalleled minimally invasive surgery with the potential to use 3mm instruments as well as innovative surgical intelligence with the addition of the ISU.”
Asensus designed Senhance as a first-of-its-kind digital laparoscopic platform for leveraging augmented intelligence to offer positive surgical outcomes through machine learning with haptic feedback, eye-tracking camera control and 3D visualization.
“We are very excited to be partnering with the Department of Gynecology at the University Hospital Tübingen, which is a leading institution in Germany, and Europe more broadly,” Asensus Surgical President and CEO Anthony Fernando said. “Tübingen’s gynecological surgery department is one of the most well respected in Europe, and we are proud they have decided to utilize Senhance within their state-of-the-art facilities.”